Loading clinical trials...
Loading clinical trials...
An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Conditions
Interventions
QBECO SSI
Locations
3
Canada
University of Alberta
Edmonton, Alberta, Canada
GI Research Institute
Vancouver, British Columbia, Canada
McMaster University
Hamilton, Ontario, Canada
Start Date
July 1, 2015
Primary Completion Date
December 1, 2016
Completion Date
December 1, 2016
Last Updated
August 24, 2017
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Qu Biologics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions